Atacama Labs Oy
This article was originally published in Start Up
Atacama Labs aims to create better oral solid-dosage forms using a pneumatic dry granulation process that it claims can granulate virtually any active drug ingredient. To prove the worth of its technology to potential clients, Atacama has applied its method to two drugs that are notoriously difficult to dry-formulate: paracetamol for pain and metformin for diabetes. That mission has been accomplished, and now Atacama is inviting drug companies to send it proprietary compounds that they deem their most difficult to formulate.
You may also be interested in...
While making money in drug delivery has always been tougher than its boosters have promised, this year's been ugly in new and disturbing ways. The key lessons of Pfizer's abandonment of inhaled insulin and Impax's patent assault on Endo's Opana are that partners are less reliable; the products need to be medically superior to existing ones, not simply more convenient; and generic companies are making inroads into the main bastion of drug-delivery success -- spec pharma.
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.